Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution

Not Applicable

Terminated

• Conditions: Block Additive; Supraclavicular Block; Regional Block for Pain Control; Ultrasound Guided Block
• Interventions: Drug: Buprenorphine

• Registration Number: NCT01583179
• Lead Sponsor: University of Wisconsin, Madison

Brief Summary

The patients included will be those who have already agreed to have a brachial plexus nerve block for surgery. A flip of the coin will decide who gets and additive called buprenorphine in their block or not. They will both contain the same amount and type of numbing medicine. The goal will be to see if the additive extends the life of the pain control portion of the ultrasound guided supraclavicular nerve block.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04
• Study First Submitted: 2012-04-19
• Study First Submitted QC: 2012-04-19
• Study First Posted: 2012-04-23
• Primary Completion: 2014-03
• Study Completion: 2015-12
• Results First Submitted: 2019-08-19
• Status Verified: 2019-09
• Results First Submitted QC: 2019-09-10
• Last Update Submitted: 2019-09-10
• Results First Posted: 2019-09-11
• Last Update Posted: 2019-09-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

1. American Society of Anesthesiologists (ASA) physical status 1-3
2. Age 18-79, inclusive
3. BMI <36 kg/m^2
4. Patient consenting to single injection brachial plexus nerve block as primary anesthetic for a procedure

Exclusion Criteria

1. Patients with coagulation disorders
2. Clinically significant pulmonary disease
3. Clinically significant cardiac disease
4. Neurologic deficit in surgical extremity
5. Allergy to bupivacaine or buprenorphine
6. Intolerance of narcotics
7. Local infection over intended area of needle insertion
8. Hepatic failure or renal failure
9. Significant psychiatric disease, including drug abuse
10. Seizure disorder
11. Possible pregnancy or lactation by patient report
12. Use of narcotic medication greater than 2 times a week for greater than 1 week.
13. Patients for whom the surgeon requests a shorter-acting block

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
buprenorphine	Buprenorphine	will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block

Primary Outcome Measures

Name	Time	Method
Time Until First Pain Medication Post-operatively	48 hrs	Time in minutes until first pain medication was take by participant post-operatively

Secondary Outcome Measures

Name	Time	Method
Pain Score on Post Operative Day 1	1 day postoperative	pain score on post operative day 1 was measured on a scale 1-10. higher scores correlates with more severe pain. score range is from '0' (no pain) to 10 (pain as severe as it can be)

Trial Locations

Locations (1)

University of Wisconsin; 🇺🇸 Madison, Wisconsin, United States